Therapeutic interventions in severe asthma

[1]  H. Watz,et al.  Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. , 2016, The Journal of allergy and clinical immunology.

[2]  P. Howarth,et al.  Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3–like protein 1 , 2016, The Journal of allergy and clinical immunology.

[3]  G. Canonica,et al.  Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs , 2016, Current opinion in allergy and clinical immunology.

[4]  G. Marone,et al.  Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study , 2016, The Journal of asthma : official journal of the Association for the Care of Asthma.

[5]  C. Akdis,et al.  Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy. , 2016, Immunology and allergy clinics of North America.

[6]  C. Marra,et al.  Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma , 2016, PloS one.

[7]  G. Canonica,et al.  Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? , 2016, Expert review of respiratory medicine.

[8]  L. Hooft,et al.  Childhood asthma prediction models: a systematic review. , 2015, The Lancet. Respiratory medicine.

[9]  G. Canonica,et al.  AIT (allergen immunotherapy): a model for the “precision medicine” , 2015, Clinical and Molecular Allergy.

[10]  C. Bachert,et al.  Allergen immunotherapy on the way to product-based evaluation—a WAO statement , 2015, The World Allergy Organization journal.

[11]  M. Weatherall,et al.  Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. , 2015, The Journal of allergy and clinical immunology.

[12]  L. Rogers,et al.  Profile of lebrikizumab and its potential in the treatment of asthma , 2015, Journal of asthma and allergy.

[13]  Borislav D. Dimitrov,et al.  Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms , 2015, The Journal of allergy and clinical immunology.

[14]  P. Demoly,et al.  Clinical contraindications to allergen immunotherapy: an EAACI position paper , 2015, Allergy.

[15]  A. Plaia,et al.  Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis. , 2015, JAMA internal medicine.

[16]  J. Zisowsky,et al.  A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects , 2015, Journal of clinical pharmacology.

[17]  Kayleigh Kew,et al.  Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. , 2015, The Cochrane database of systematic reviews.

[18]  D. Bernstein,et al.  Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. , 2015, The Journal of allergy and clinical immunology.

[19]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[20]  C. Bachert,et al.  Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. , 2015, The New England journal of medicine.

[21]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[22]  E. Bleecker,et al.  Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. , 2015, The Lancet. Respiratory medicine.

[23]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[24]  L. Boulet,et al.  Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults , 2014, European Respiratory Review.

[25]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[26]  J. Arm,et al.  Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  G. Canonica,et al.  SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial. , 2014, Respiratory medicine.

[28]  Christopher Dye,et al.  The international Ebola emergency. , 2014, The New England journal of medicine.

[29]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[30]  G. Canonica,et al.  Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of allergy and clinical immunology.

[31]  J. Bell,et al.  Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459 , 2014, Allergy.

[32]  R. Thurmond,et al.  The histamine H4 receptor is a potent inhibitor of adhesion‐dependent degranulation in human neutrophils , 2014, Journal of leukocyte biology.

[33]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[34]  P. Devillier,et al.  House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma , 2014, Allergy.

[35]  P. Burton,et al.  Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability , 2014, PloS one.

[36]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[37]  M. Raffeld,et al.  The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders. , 2014, The Journal of allergy and clinical immunology.

[38]  D. Curran‐Everett,et al.  Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. , 2014, The Journal of allergy and clinical immunology.

[39]  L. Boulet,et al.  Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo‐controlled clinical trial , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  J. Bousquet,et al.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.

[41]  G. Passalacqua.  Specific immunotherapy in asthma: a comprehensive review , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[42]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[43]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[44]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[45]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[46]  J. Bousquet,et al.  A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics , 2013, The World Allergy Organization journal.

[47]  Ruksha Bhadresha.  Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[48]  Hana Hazgui,et al.  Ten-year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts. , 2013, American journal of respiratory and critical care medicine.

[49]  I. Pavord,et al.  Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. , 2013, The Journal of allergy and clinical immunology.

[50]  J. Bousquet,et al.  Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. , 2013, The Journal of allergy and clinical immunology.

[51]  A. Sheikh,et al.  EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy , 2012, Clinical and Translational Allergy.

[52]  Michael Engel,et al.  Tiotropium in asthma poorly controlled with standard combination therapy. , 2012, The New England journal of medicine.

[53]  H. Ortega,et al.  Novel targeted therapies for eosinophilic disorders. , 2012, The Journal of allergy and clinical immunology.

[54]  P. O'Byrne,et al.  Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo‐controlled clinical trial , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[55]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[56]  W. Busse,et al.  Omalizumab and the risk of malignancy: results from a pooled analysis. , 2012, The Journal of allergy and clinical immunology.

[57]  J. Drazen,et al.  A patient with asthma seeks medical advice in 1828, 1928, and 2012. , 2012, The New England journal of medicine.

[58]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[59]  G. Passalacqua.  Specific immunotherapy: beyond the clinical scores. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[60]  H. Simon,et al.  Hypereosinophilia in patients with multiple sclerosis treated with natalizumab , 2011, Neurology.

[61]  G. Canonica,et al.  Specific immunotherapy in asthma: efficacy and safety , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[62]  E. Bateman,et al.  Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. , 2011, The Journal of allergy and clinical immunology.

[63]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[64]  K. Aozasa,et al.  SIRPα/CD172a Regulates Eosinophil Homeostasis , 2011, The Journal of Immunology.

[65]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[66]  I. Pavord,et al.  Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.

[67]  P. Kardos,et al.  Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. , 2010, The Journal of allergy and clinical immunology.

[68]  V. Scafidi,et al.  Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. , 2010, The Journal of allergy and clinical immunology.

[69]  R. Puy,et al.  Injection allergen immunotherapy for asthma. , 2010, The Cochrane database of systematic reviews.

[70]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[71]  R. Lockey,et al.  Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. , 2010, The Journal of allergy and clinical immunology.

[72]  H. Nakajima,et al.  Role of IL-23 and Th17 Cells in Airway Inflammation in Asthma , 2010, Immune network.

[73]  Mario Castro,et al.  Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. , 2010, American journal of respiratory and critical care medicine.

[74]  L. Cox,et al.  Comparison of allergen immunotherapy practice patterns in the United States and Europe. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[75]  G. Passalacqua,et al.  The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA²LEN meta‐analysis , 2009, Allergy.

[76]  J. Kolls,et al.  Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. , 2009, American journal of respiratory and critical care medicine.

[77]  G. Passalacqua,et al.  A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[78]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[79]  R. Egan,et al.  The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases , 2009, Journal of Pharmacology and Experimental Therapeutics.

[80]  A. Gulsvik,et al.  Asthma Severity According to Global Initiative for Asthma and Its Determinants: An International Study , 2009, International Archives of Allergy and Immunology.

[81]  S. Holgate,et al.  Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[82]  E. Kerwin,et al.  A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. , 2009, American journal of respiratory and critical care medicine.

[83]  B. Bochner.  Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[84]  L. Cox.  Allergen immunotherapy and asthma: efficacy, safety, and other considerations. , 2008, Allergy and asthma proceedings.

[85]  D. Jarvis,et al.  Rhinitis and onset of asthma: a longitudinal population-based study , 2008, The Lancet.

[86]  G. Canonica,et al.  Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[87]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[88]  M. Rothenberg,et al.  A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. , 2008, Blood.

[89]  E. Burchard,et al.  Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[90]  C. Baena-Cagnani,et al.  Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. , 2008, Chest.

[91]  J Bousquet,et al.  Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update , 2007, Allergy.

[92]  L. Bjermer.  Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. , 2007, The Journal of allergy and clinical immunology.

[93]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[94]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[95]  P. Scheinmann,et al.  Assessment of sublingual immunotherapy efficacy in children with house dust mite‐induced allergic asthma optimally controlled by pharmacologic treatment and mite‐avoidance measures , 2007, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[96]  T. Lasserson,et al.  Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. , 2006, The Cochrane database of systematic reviews.

[97]  H. Saconato,et al.  Efficacy of sublingual immunotherapy in asthma: systematic review of randomized‐clinical trials using the Cochrane Collaboration method , 2006, Allergy.

[98]  P. Barnes,et al.  The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma , 2006 .

[99]  I. Bachelet,et al.  The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. , 2006, Blood.

[100]  R. Dahl,et al.  Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis , 2006, Allergy.

[101]  J. Kleine‐Tebbe,et al.  Safety of a SQ‐standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo‐controlled trial , 2006, Allergy.

[102]  S. Durham,et al.  Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. , 2006, The Journal of allergy and clinical immunology.

[103]  M. Rothenberg,et al.  Inhibition of human interleukin‐13‐induced respiratory and oesophageal inflammation by anti‐human‐interleukin‐13 antibody (CAT‐354) , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[104]  C. Ding,et al.  Bertilimumab Cambridge Antibody Technology Group. , 2004, Current opinion in investigational drugs.

[105]  S. Burastero,et al.  Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. , 2004, The Journal of allergy and clinical immunology.

[106]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[107]  J. Cuesta-Herranz,et al.  Immunotherapy safety: a prospective multi‐centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[108]  R. Puy,et al.  Allergen immunotherapy for asthma. , 2003, The Cochrane database of systematic reviews.

[109]  B. Bochner,et al.  Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.

[110]  E. Nettis,et al.  Safety of inhalant allergen immunotherapy with mass units‐standardized extracts , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[111]  M. Brigham-Burke,et al.  Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti‐interleukin‐4 antibody with therapeutic potential in asthma , 2002, Clinical and experimental immunology.

[112]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[113]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[114]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[115]  G. Canonica,et al.  Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. , 1997, Journal of investigational allergology & clinical immunology.

[116]  R. Puy,et al.  Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. , 1995, American journal of respiratory and critical care medicine.

[117]  R. Lockey,et al.  Survey of fatalities from skin testing and immunotherapy 1985-1989. , 1993, The Journal of allergy and clinical immunology.

[118]  R. Lockey,et al.  Fatalities from immunotherapy (IT) and skin testing (ST) , 1987, The Journal of allergy and clinical immunology.

[119]  D. Johnstone,et al.  The value of hyposensitization therapy for bronchial asthma in children--a 14-year study. , 1968, Pediatrics.

[120]  R. Silverman,et al.  A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. , 2015, The American journal of emergency medicine.

[121]  C. Pontes,et al.  Is the H4 receptor a new drug target for allergies and asthma? , 2013, Frontiers in bioscience.

[122]  B. Hargadon,et al.  Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. , 2012, The Journal of allergy and clinical immunology.

[123]  F. Mellot,et al.  Sustained response to mepolizumab in refractory Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[124]  G. Liss,et al.  Evaluation of near-fatal reactions to allergen immunotherapy injections. , 2006, The Journal of allergy and clinical immunology.

[125]  P. Barnes,et al.  The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. , 2006, American journal of respiratory and critical care medicine.

[126]  [WHO position paper. "Allergen immunotherapy: therapeutic vaccines for allergic diseases"]. , 1998, Arerugi = [Allergy].